Multiple CDMOs secured significant contract manufacturing opportunities as regulatory bodies approved new indications for established drugs, particularly in oncology and rare diseases.
Alzinova AB has successfully released the drug substance for its ALZ-101 vaccine candidate, enabling final drug product manufacturing for an upcoming Phase 2 clinical trial in early Alzheimer's disease scheduled to begin in the second half of 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.